VistaGen Therapeutics Receives FDA Clearance of IND for Phase 2 Clinical Study of AV-101 as a Potential Treatment of Dyskinesia in Parkinson's Disease Patients

The FDA's IND clearance permits VistaGen to proceed with Phase 2 clinical development of AV-101 in this indication.